49 - Genetics and Pathophysiology of Cystic Fibrosis

Garry R. Cutting, John Engelhardt, Pamela Leslie Zeitlin

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Scopus citations


Our understanding of the role of disease-causing variants in CFTR has culminated in two new variant-specific CFTR modulator therapies approved by the US FDA. These modulators target defects in CFTR biogenesis and in channel gating. Clinical trials are directed to improving the efficacy of these first-generation molecules. However, other CFTR variants that lead to nonsense-mediated decay, aberrant splicing, and reduced gene expression are refractory to CFTR modulators and will require new therapeutic approaches. To this end, new CF animal models are yielding key insights into tissue-specific disease mechanisms, such as impaired mucociliary clearance and pancreatic dysfunction. Although infection and inflammation remain challenging to treat, progress in targeting CFTR directly will result in individuals with CF living longer. To maximize life span, earlier interventions, soon after diagnosis, are needed. Finally, the advances in precision medicine for CF may benefit more common disorders such as COPD and pancreatitis where CFTR dysfunction contributes to pathophysiology.

Original languageEnglish (US)
Title of host publicationKendig's Disorders of the Respiratory Tract in Children
PublisherElsevier Inc.
ISBN (Electronic)9780323555951
ISBN (Print)9780323448871
StatePublished - 2019


  • CFTR
  • Chloride
  • DNA variant
  • Nonsense-mediated decay
  • Protein folding
  • Sodium
  • Splicing

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of '49 - Genetics and Pathophysiology of Cystic Fibrosis'. Together they form a unique fingerprint.

Cite this